In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

There remains a need to identify patients who will derive benefits from adjunctive techniques on top of pulmonary vein ...

Many hope My Heart Your Heart will catalyze an effort to help patients worldwide who need but can’t afford these devices.

Compared with placebo, sodium zirconium cyclosilicate was associated with less need to lower or discontinue spironolactone.

The India-based trial, the first of its kind, confirmed that systolic BP levels decreased no matter the exact mix of three ...

The observed changes were favorable, but results may have been affected by better-than-normal care in the control arm.

Two studies presented at AHA show the capacity of AI to improve sonographer accuracy, consistency, and workflow.

The mixed, counterintuitive results hinder trial interpretation, but along with ARREST-AF, experts still see actionable ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

In positive early data from the RCT, sacubitril/valsartan given over 24 weeks reduced signs of heart damage in cancer ...

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

By targeting the TTR gene directly in the liver, the therapy “has opened up the door” to permanent treatment, says Sarah ...